scholarly journals 176: Evaluating use of FEV1 decline in diagnosis and management of pulmonary exacerbations in children with cystic fibrosis

2021 ◽  
Vol 20 ◽  
pp. S87
Author(s):  
D. Bouzek ◽  
M. Thompson ◽  
J. Slaven ◽  
C. Ren ◽  
D. Sanders
2019 ◽  
Vol 76 (11) ◽  
pp. 1110-1114
Author(s):  
Bojana Gojsina ◽  
Milan Rodic ◽  
Jelena Visekruna ◽  
Goran Trajkovic ◽  
Aleksandar Sovtic ◽  
...  

Background/Aim. Pulmonary exacerbations have negative impact on clinical course of cystic fibrosis (CF) lung disease being associated with a steeper decline in the lung function, unfavorable prognosis and impaired quality of life. The aim of this study was to determine whether an increased number of exacerbations had influence on the lung function in the patients with CF, as well as to estimate the nutritional status, gender, presence of comorbid conditions and bacterial colonization of airways as predictive factors for pulmonary exacerbations. Methods. This retrospective cohort study included 83 pediatric and adult patients, treated from 2011? 2015 in the Mother and Child Health Institute of Serbia ?Dr Vukan Cupic?. The best result of forced expiratory volume in the first second (FEV1) and forced vital capacity (FVC) in each year of follow-up was taken into account to calculate the five-year trend values of these indicators. The number of exacerbations per year of follow-up and its impact on the FEV1 decline was evaluated. Results. Mean annual decline of FEV1 and FVC were 2.4% and 1.7% respectively. The malnourished patients had the lower initial values of FEV1 and FVC, and more frequent exacerbations in comparison with the normal weight and overweight patients. The frequency of exacerbations was significantly higher in the patients chronically colonized with Burkholderia cepacia (p = 0.023). The increased number of exacerbation was proved to be the most important factor in a prediction of FEV1 decline over time (p = 0.013). Conclusion. Pulmonary exacerbations lead to the more progressive lung function decline in the patients with CF. Malnourishment and chronic airway colonization with Burkholderia cepacia result in more frequent pulmonary exacerbations.


Thorax ◽  
2012 ◽  
Vol 67 (Suppl 2) ◽  
pp. A101.3-A102
Author(s):  
WG Flight ◽  
KJ Mutton ◽  
AK Webb ◽  
RJ Bright-Thomas ◽  
AM Jones

2010 ◽  
Vol 46 (4) ◽  
pp. 393-400 ◽  
Author(s):  
Don B. Sanders ◽  
Rachel CL. Bittner ◽  
Margaret Rosenfeld ◽  
Gregory J. Redding ◽  
Christopher H. Goss

2021 ◽  
Vol 8 (1) ◽  
pp. e000956
Author(s):  
Grace Currie ◽  
Anna Tai ◽  
Tom Snelling ◽  
André Schultz

BackgroundDespite advances in cystic fibrosis (CF) management and survival, the optimal treatment of pulmonary exacerbations remains unclear. Understanding the variability in treatment approaches among physicians might help prioritise clinical uncertainties to address through clinical trials.MethodsPhysicians from Australia and New Zealand who care for people with CF were invited to participate in a web survey of treatment preferences for CF pulmonary exacerbations. Six typical clinical scenarios were presented; three to paediatric and another three to adult physicians. For each scenario, physicians were asked to choose treatment options and provide reasons for their choices.ResultsForty-nine CF physicians (31 paediatric and 18 adult medicine) participated; more than half reported 10+ years of experience. There was considerable variation in primary antibiotic selection; none was preferred by more than half of respondents in any scenario. For secondary antibiotic therapy, respondents consistently preferred intravenous tobramycin and a third antibiotic was rarely prescribed, except in one scenario describing an adult patient. Hypertonic saline nebulisation and twice daily chest physiotherapy was preferred in most scenarios while dornase alfa use was more variable. Most CF physicians (>80%) preferred to change therapy if there was no early response. Professional opinion was the most common reason for antibiotic choice.ConclusionsVariation exists among CF physicians in their preferred choice of primary antibiotic and use of dornase alfa. These preferences are driven by professional opinion, possibly reflecting a lack of evidence to base policy recommendations. Evidence from high-quality clinical trials is needed to inform physician decision making.


1986 ◽  
Vol 75 (1) ◽  
pp. 128-138 ◽  
Author(s):  
U. B. SCHAAD ◽  
D. DESGRANDCHAMPS ◽  
R. KRAEMER

2014 ◽  
Vol 14 (1) ◽  
Author(s):  
Rosa Maria Girón-Moreno ◽  
José L Justicia ◽  
Sara Yamamoto ◽  
Claudia Valenzuela ◽  
Carolina Cisneros ◽  
...  

Thorax ◽  
2016 ◽  
Vol 72 (4) ◽  
pp. 327-332 ◽  
Author(s):  
Sanja Stanojevic ◽  
Alexandra McDonald ◽  
Valerie Waters ◽  
Sarah MacDonald ◽  
Eric Horton ◽  
...  

2011 ◽  
Vol 46 (9) ◽  
pp. 870-881 ◽  
Author(s):  
Nathan C. Kraynack ◽  
M. David Gothard ◽  
Lynn M. Falletta ◽  
John T. McBride

Sign in / Sign up

Export Citation Format

Share Document